

# Financial Tear Sheet

## Corporate Profile

Who is Organovo?

- We participate in attractive and growing markets with critical unmet needs
- We benefit from favorable competitive dynamics and a first mover advantage
- We're a technology leader with a strong IP portfolio
- We're leveraging our technology platform to build a robust product and service platform across the high-value drug profiling and therapeutic tissues markets

 [2018 Annual Report](#)    [Investor Presentation](#)

## Primary IR Contact

Steve E. Kunszabo  
 VP, Investor Relations &  
 Corporate  
 Communications  
**Phone:** 858-224-1092  
**Email:**  
[skunszabo@organovo.com](mailto:skunszabo@organovo.com)

## Stock Information

ONVO (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	<b>\$1.28</b>
Change (%)	▼ 0.04 (3.03%)
Volume	1,036,193
52 Week Low	\$0.91
Market Cap	\$142,242,080
Rolling EPS	-0.33
PE Ratio	0
Shares Outstanding	111,126,625
Data as of 07/20/18 4:00 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

## Recent Press Releases & Upcoming Events

07/19/18

Organovo Announces Release Date for Fiscal First-Quarter 2019 Financial Results

05/31/18

Organovo Reports Fiscal Fourth-Quarter and Full-Year 2018 Results; Company Announces Key Goals for Fiscal-Year 2019

05/14/18

Organovo Announces Release Date for Fiscal Fourth-Quarter 2018 Financial Results

Date	Title
08/09/18 5:00 p.m. ET	<b>Organovo Holdings, Inc. First Quarter Earnings Conference Call</b>

## SEC Filings

Filing Date	Form
06/26/18	4
06/15/18	DEFA14A
06/15/18	DEF 14A
06/01/18	PRE 14A

## Corporate Governance

Taylor J. Crouch	President & Chief Executive Officer
Sharon Collins Presnell, Ph.D.	Chief Scientific Officer, Organovo & President, Samsara
Eric Michael David, M.D., J.D.	Chief Strategy Officer and Executive Vice President of Preclinical Development
Jennifer Kinsbruner Bush, J.D.	General Counsel, Corporate Secretary and Compliance Officer
Susan Daugherty	Senior Vice President, Human Resources
Paul Gallant	General Manager